Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 5/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 4/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | TEK | Q02763 | 3/20 | 0.33 |
| ▸ | JUN | P05412 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
| ▸ | INSR | P06213 | 1/20 | 0.32 |
| ▸ | FES | P07332 | 1/20 | 0.32 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
| ▸ | LYN | P07948 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5066068 | 0.93 | CASR (0.40) | CASRLMNAF10JUNNFKB1 | |
| SCHEMBL5065185 | 0.90 | LCK (0.39) | CASRLCKLMNAKDRMAPK14 | |
| SCHEMBL5065208 | 0.90 | CASR (0.31) | CASRF10NTRK1RXFP1MTTP | |
| SCHEMBL5061983 | 0.89 | TRPV1 (0.35) | F10RXFP1MTTP | |
| SCHEMBL5065150 | 0.87 | MTTP (0.41) | MTTP | |
| SCHEMBL5062419 | 0.84 | MTTP (0.36) | MTTP | |
| SCHEMBL5066043 | 0.82 | CASR (0.43) | CASRLMNAF10JUNNFKB1 | |
| SCHEMBL5061900 | 0.82 | MTTP (0.38) | MTTP | |
| SCHEMBL5068141 | 0.80 | MTTP (0.39) | MTTP | |
| SCHEMBL5064982 | 0.80 | MTTP (0.39) | MTTP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432392-B2 | Ester derivatives and medical use thereof | JAPAN TOBACCO INC. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-20060205726-A1 | Ester derivatives and medical use thereof | JAPAN TOBACCO INC. (JP) | 2006-09-14 | — | — | US | disclosed |
| EP-1669345-A1 | ESTER DERIVATIVE AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2006-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205726-A1 | Ester derivatives and medical use thereof | MTTP, LIPC, CETP | CASR 4802/4885LCK 3393/4885LMNA 2938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.